This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market. It also advances next-generation peptide therapeutics, including those for metabolics, supporting the long-term strategic growth of both organizations.
As part of the alliance, both companies will work towards the following:
Expanding sourcing options and fortifying peptide supply chains to meet rising global demand for peptide APIs, including for metabolic disease therapies.
Integrating procurement and supply planning
Ensuring unwavering quality and reliability and delivering superior service globally
This partnership strengthens Lupin Manufacturing Solutions as a CDMO supplier of peptide materials for both innovator and generic markets.
Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, “We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide.”
"Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including preparations for large-scale metabolics,” said Stéphane Varray, Chief Commercial Officer, PolyPeptide. “When you’re enabling life-changing therapies, your supply chain must operate as a true strategic capability.”
Lupin Manufacturing Solutions Limited, a 100% subsidiary of
Lupin Limited, is a manufacturer of active pharmaceutical ingredients (APIs) and a global contract development and manufacturing organization (CDMO) offering standalone & integrated solutions across drug substances, complex chemistry, drug product, and advanced modalities, including ADCs and peptides. Lupin Manufacturing Solutions supports biopharma innovators from early development to commercial scale.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.